315 related articles for article (PubMed ID: 30747241)
1. Radiochemotherapy combined with NK cell transfer followed by second-line PD-1 inhibition in a patient with NSCLC stage IIIb inducing long-term tumor control: a case study.
Kokowski K; Stangl S; Seier S; Hildebrandt M; Vaupel P; Multhoff G
Strahlenther Onkol; 2019 Apr; 195(4):352-361. PubMed ID: 30747241
[TBL] [Abstract][Full Text] [Related]
2.
Shevtsov M; Pitkin E; Ischenko A; Stangl S; Khachatryan W; Galibin O; Edmond S; Lobinger D; Multhoff G
Front Immunol; 2019; 10():454. PubMed ID: 30967859
[TBL] [Abstract][Full Text] [Related]
3. Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial.
Multhoff G; Seier S; Stangl S; Sievert W; Shevtsov M; Werner C; Pockley AG; Blankenstein C; Hildebrandt M; Offner R; Ahrens N; Kokowski K; Hautmann M; Rödel C; Fietkau R; Lubgan D; Huber R; Hautmann H; Duell T; Molls M; Specht H; Haller B; Devecka M; Sauter A; Combs SE
Clin Cancer Res; 2020 Oct; 26(20):5368-5379. PubMed ID: 32873573
[TBL] [Abstract][Full Text] [Related]
4. Correlation of Hsp70 Serum Levels with Gross Tumor Volume and Composition of Lymphocyte Subpopulations in Patients with Squamous Cell and Adeno Non-Small Cell Lung Cancer.
Gunther S; Ostheimer C; Stangl S; Specht HM; Mozes P; Jesinghaus M; Vordermark D; Combs SE; Peltz F; Jung MP; Multhoff G
Front Immunol; 2015; 6():556. PubMed ID: 26579130
[TBL] [Abstract][Full Text] [Related]
5. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial.
Krause SW; Gastpar R; Andreesen R; Gross C; Ullrich H; Thonigs G; Pfister K; Multhoff G
Clin Cancer Res; 2004 Jun; 10(11):3699-707. PubMed ID: 15173076
[TBL] [Abstract][Full Text] [Related]
6. Heat Shock Protein 70 (Hsp70) Peptide Activated Natural Killer (NK) Cells for the Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) after Radiochemotherapy (RCTx) - From Preclinical Studies to a Clinical Phase II Trial.
Specht HM; Ahrens N; Blankenstein C; Duell T; Fietkau R; Gaipl US; Günther C; Gunther S; Habl G; Hautmann H; Hautmann M; Huber RM; Molls M; Offner R; Rödel C; Rödel F; Schütz M; Combs SE; Multhoff G
Front Immunol; 2015; 6():162. PubMed ID: 25926832
[TBL] [Abstract][Full Text] [Related]
7. Elevated Levels of Circulating Hsp70 and an Increased Prevalence of CD94+/CD69+ NK Cells Is Predictive for Advanced Stage Non-Small Cell Lung Cancer.
Seier S; Bashiri Dezfouli A; Lennartz P; Pockley AG; Klein H; Multhoff G
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428793
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of tumor growth in mice with severe combined immunodeficiency is mediated by heat shock protein 70 (Hsp70)-peptide-activated, CD94 positive natural killer cells.
Moser C; Schmidbauer C; Gürtler U; Gross C; Gehrmann M; Thonigs G; Pfister K; Multhoff G
Cell Stress Chaperones; 2002 Oct; 7(4):365-73. PubMed ID: 12653481
[TBL] [Abstract][Full Text] [Related]
9. A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study.
Yang YJ; Park JC; Kim HK; Kang JH; Park SY
Anticancer Res; 2013 May; 33(5):2115-22. PubMed ID: 23645763
[TBL] [Abstract][Full Text] [Related]
10. Combination of PD-1 blockade and RetroNectin
Zhao L; Han L; Zhang Y; Li T; Yang Y; Li W; Shang Y; Lin H; Gao Q
Immunotherapy; 2018 Nov; 10(15):1315-1323. PubMed ID: 30350739
[TBL] [Abstract][Full Text] [Related]
11. The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC.
Mazzaschi G; Facchinetti F; Missale G; Canetti D; Madeddu D; Zecca A; Veneziani M; Gelsomino F; Goldoni M; Buti S; Bordi P; Aversa F; Ardizzoni A; Quaini F; Tiseo M
Lung Cancer; 2019 Jan; 127():153-163. PubMed ID: 30642544
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor activity of patient-derived NK cells after cell-based immunotherapy--a case report.
Milani V; Stangl S; Issels R; Gehrmann M; Wagner B; Hube K; Mayr D; Hiddemann W; Molls M; Multhoff G
J Transl Med; 2009 Jun; 7():50. PubMed ID: 19549307
[TBL] [Abstract][Full Text] [Related]
13. Heat shock protein 70-reactivity is associated with increased cell surface density of CD94/CD56 on primary natural killer cells.
Gross C; Schmidt-Wolf IG; Nagaraj S; Gastpar R; Ellwart J; Kunz-Schughart LA; Multhoff G
Cell Stress Chaperones; 2003; 8(4):348-60. PubMed ID: 15115287
[TBL] [Abstract][Full Text] [Related]
14. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
15. CAR T Cells Targeting Membrane-Bound Hsp70 on Tumor Cells Mimic Hsp70-Primed NK Cells.
Bashiri Dezfouli A; Yazdi M; Benmebarek MR; Schwab M; Michaelides S; Miccichè A; Geerts D; Stangl S; Klapproth S; Wagner E; Kobold S; Multhoff G
Front Immunol; 2022; 13():883694. PubMed ID: 35720311
[TBL] [Abstract][Full Text] [Related]
16. Influence of In Vitro IL-2 or IL-15 Alone or in Combination with Hsp 70 Derived 14-Mer Peptide (TKD) on the Expression of NK Cell Activatory and Inhibitory Receptors on Peripheral Blood T Cells, B Cells and NKT Cells.
Hromadnikova I; Li S; Kotlabova K; Dickinson AM
PLoS One; 2016; 11(3):e0151535. PubMed ID: 26982331
[TBL] [Abstract][Full Text] [Related]
17. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
[TBL] [Abstract][Full Text] [Related]
18. Control of metastasized pancreatic carcinomas in SCID/beige mice with human IL-2/TKD-activated NK cells.
Stangl S; Wortmann A; Guertler U; Multhoff G
J Immunol; 2006 May; 176(10):6270-6. PubMed ID: 16670338
[TBL] [Abstract][Full Text] [Related]
19. Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade.
Fang L; Ly D; Wang SS; Lee JB; Kang H; Xu H; Yao J; Tsao MS; Liu W; Zhang L
J Exp Clin Cancer Res; 2019 Mar; 38(1):123. PubMed ID: 30857561
[TBL] [Abstract][Full Text] [Related]
20. TUSC2 Immunogene Therapy Synergizes with Anti-PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic
Meraz IM; Majidi M; Cao X; Lin H; Li L; Wang J; Baladandayuthapani V; Rice D; Sepesi B; Ji L; Roth JA
Cancer Immunol Res; 2018 Feb; 6(2):163-177. PubMed ID: 29339375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
